Analyst Profile

Followed by 158 followers
.
Maury Raycroft

Maury Raycroft

Jefferies
Wall Street Analyst
#2,603 out of 8,141 Wall Street Analysts
#5,725 out of 24,284 experts

Success Rate

40%
82 out of 205 transactions made a profit

Average Return

+3.40%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
Copying Maury Raycroft's trades since 2017 and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of 3.4% per rating.

Stock Rating Distribution

250Ratings
86.00% Buy
14.00% Hold
0.00% Sell
Distribution of Maury Raycroft's ratings

Additional Information

Main Sector:General
Geo Coverage:
United StatesUS Market
United KingdomUK Market

Best Rating

Stock:
BioCryst Pharmaceuticals
(BCRX)
Rating:Buy
Date:Aug 10, 2020 - Aug 09, 2021
Return:+327.30%
The most profitable rating made by Maury Raycroft

Maury Raycroft's Stock Coverage

Company
Date
Position
Action
Price Target
No. of Ratings
Success Rate
Avg. Return
~RXDX
Ignyta Inc
Dec 22, 2017
Hold
Downgraded
1Ratings
0.00%
Abeona Therapeutics
May 22, 2018
Buy
Reiterated
$28.00
(617.95% Upside)
2Ratings
0%
-54.10%
Xenon
Aug 10, 2018
Buy
Reiterated
$16.00
(-54.04% Downside)
6Ratings
80%
+72.18%
ECYT
Endocyte
Sep 10, 2018
Buy
Reiterated
4Ratings
100%
+82.75%
IMDZ
Immune Design
Oct 12, 2018
Buy
Reiterated
4Ratings
75%
+74.95%
OMED
OncoMed Pharma
Dec 06, 2018
Hold
Downgraded
3Ratings
0%
-50.80%
IDEAYA Biosciences
Jun 17, 2019
Buy
Initiated
$14.00
(-20.36% Downside)
1Ratings
100%
+70.00%
Sangamo Biosciences
Jul 12, 2019
Buy
Reiterated
$19.00
(433.71% Upside)
5Ratings
0%
-27.22%
F-star Therapeutics
Jan 29, 2020
Hold
Downgraded
$6.00
(2.56% Upside)
2Ratings
0%
-78.90%
Black Diamond Therapeutics
Feb 24, 2020
Buy
Initiated
$47.00
(2055.96% Upside)
1Ratings
0%
-14.20%
List of latest recommendations made by Maury Raycroft. Click to expand and see Maury Raycroft's performance on a particular stock
Disclaimer: TipRanks collects analysts’ ratings and price targets by scanning publicly available reports on financial websites and by receiving reports from analysts, firms, or customers. The information and statistics displayed might not be accurate, complete, or up-to-date. The analyst ratings provided are the sole responsibility of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings, or opinions expressed.
Send Us Reports
If you receive reports that you think we are missing, we will thank you with a free Ultimate upgrade!
Learn More >